Cellebrite DI Ltd.(CLBT)Earnings, Financials & Key Ratios
CLBT•NASDAQ
$13.17
$3.22B mkt cap·42.5× P/E·Price updated May 6, 2026
SectorTechnologyIndustryInfrastructure SoftwareSub-IndustryData platforms, integration and analytics
AboutCellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.Show more
- Revenue$476M+18.6%
- EBITDA$78M+16.0%
- Net Income$78M+127.7%
- EPS (Diluted)0.31+123.0%
- Gross Margin84.2%-0.2%
- EBITDA Margin16.47%-2.1%
- Operating Margin13.98%-1.5%
- Net Margin16.47%+123.3%
- ROE19.1%+112.5%
- ROIC18.54%-96.9%
- Debt/Equity0.05+43.4%
CLBT Key Insights
Cellebrite DI Ltd. (CLBT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 68.4%
- ✓FCF machine: 33.7% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 19.5%
✗Weaknesses
- ✗Shares diluted 19.3% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLBT Price & Volume
Cellebrite DI Ltd. (CLBT) stock price & volume — 10-year historical chart
Loading chart...
CLBT Growth Metrics
Cellebrite DI Ltd. (CLBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.53%
3 Years20.68%
TTM18.56%
Profit CAGR
10 Years-
5 Years68.41%
3 Years-13.45%
TTM127.68%
EPS CAGR
10 Years-
5 Years58.59%
3 Years-19.31%
TTM122.2%
Return on Capital
10 Years8.13%
5 Years10.6%
3 Years14.89%
Last Year13.79%
CLBT Recent Earnings
Cellebrite DI Ltd. (CLBT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 11, 2026EPS
$0.09
Est $0.14
-35.7%
Revenue
$129M
Est $126M
+2.1%
Q4 2025
Nov 12, 2025EPS
$0.14
Est $0.09
+48.2%
Revenue
$126M
Est $123M
+2.5%
Q3 2025
Aug 14, 2025EPS
$0.12
Est $0.10
+20.0%
Revenue
$113M
Est $112M
+1.0%
Q2 2025
May 14, 2025EPS
$0.10
Est $0.05
+90.3%
Revenue
$108M
Est $109M
-1.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 11, 2026 | $0.09vs $0.14-35.7% | $129Mvs $126M+2.1% |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.09+48.2% | $126Mvs $123M+2.5% |
| Q3 2025 | Aug 14, 2025 | $0.12vs $0.10+20.0% | $113Mvs $112M+1.0% |
| Q2 2025 | May 14, 2025 | $0.10vs $0.05+90.3% | $108Mvs $109M-1.6% |
Based on last 12 quarters of dataView full earnings history →
CLBT Peer Comparison
Cellebrite DI Ltd. (CLBT) competitors in Data platforms, integration and analytics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AXON | 31.09B | 385.86 | 255.54 | 33.47% | 6.91% | 6.58% | 0.59 | |
 VRNS | 3.24B | 27.61 | -24.43 | 13.17% | -20.71% | -27.37% | 0.96 | |
 OSPN | 442.11M | 11.80 | 6.21 | 0% | 28.47% | 27.31% | 0.02 | |
 NTCT | 2.57B | 35.52 | -7.02 | -0.82% | 11.13% | 6.07% | 0.05 | |
 IIIV | 486.07M | 22.00 | 39.29 | -7.29% | 7.33% | 3.22% | 0.01 | |
 SPSC | 2.09B | 55.87 | 22.71 | 17.83% | 11.92% | 9.45% | 0.01 | |
 CACI | 11.03B | 499.42 | 22.38 | 12.64% | 5.86% | 13.15% | 0.86 | |
 SAIC | 4.25B | 94.36 | 12.25 | -2.9% | 4.93% | 23.73% | 0.14 |
Compare CLBT vs Peers
Cellebrite DI Ltd. (CLBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLBT Income Statement
Cellebrite DI Ltd. (CLBT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 171.85M | 194.91M | 246.25M | 270.65M | 325.11M | 401.2M | 475.68M |
| Revenue Growth % | - | 13.42% | 26.34% | 9.91% | 20.12% | 23.41% | 18.56% |
| Cost of Goods Sold | 35.82M | 37.88M | 42.56M | 50.75M | 53.23M | 62.59M | 75.17M |
| COGS % of Revenue | 20.84% | 19.43% | 17.28% | 18.75% | 16.37% | 15.6% | 15.8% |
| Gross Profit | 136.03M▲ 0% | 157.03M▲ 15.4% | 203.69M▲ 29.7% | 219.91M▲ 8.0% | 271.88M▲ 23.6% | 338.61M▲ 24.5% | 400.5M▲ 18.3% |
| Gross Margin % | 79.16% | 80.57% | 82.72% | 81.25% | 83.63% | 84.4% | 84.2% |
| Gross Profit Growth % | - | 15.44% | 29.71% | 7.96% | 23.63% | 24.54% | 18.28% |
| Operating Expenses | 137.55M | 147.82M | 189.87M | 218.86M | 238.64M | 281.7M | 334.02M |
| OpEx % of Revenue | 80.04% | 75.84% | 77.1% | 80.86% | 73.4% | 70.21% | 70.22% |
| Selling, General & Admin | 90.23M | 91.17M | 124.33M | 138.24M | 154.26M | 183.29M | 220.15M |
| SG&A % of Revenue | 52.5% | 46.77% | 50.49% | 51.08% | 47.45% | 45.68% | 46.28% |
| Research & Development | 46.57M | 54.38M | 65.54M | 80.62M | 84.39M | 98.42M | 113.88M |
| R&D % of Revenue | 27.1% | 27.9% | 26.62% | 29.79% | 25.96% | 24.53% | 23.94% |
| Other Operating Expenses | 750K | 2.27M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.52M▲ 0% | 9.22M▲ 706.4% | 13.82M▲ 49.9% | 1.04M▼ 92.4% | 33.24M▲ 3083.6% | 56.91M▲ 71.2% | 66.48M▲ 16.8% |
| Operating Margin % | -0.88% | 4.73% | 5.61% | 0.39% | 10.22% | 14.18% | 13.98% |
| Operating Income Growth % | - | 706.45% | 49.95% | -92.45% | 3083.62% | 71.21% | 16.82% |
| EBITDA | 2.56M | 15.1M | 20.83M | 10.24M | 43.25M | 67.51M | 78.35M |
| EBITDA Margin % | 1.49% | 7.75% | 8.46% | 3.78% | 13.3% | 16.83% | 16.47% |
| EBITDA Growth % | - | 489.96% | 37.97% | -50.85% | 322.43% | 56.11% | 16.05% |
| D&A (Non-Cash Add-back) | 4.08M | 5.88M | 7.01M | 9.19M | 10.01M | 10.61M | 11.87M |
| EBIT | 1.54M | 11.4M | 82.46M | 120.91M | -74.81M | 56.91M | 66.48M |
| Net Interest Income | 3.12M | 1.4M | 694K | 1.88M | 8.89M | -331.54M | 0 |
| Interest Income | 3.48M | 2.82M | 847K | 2.02M | 8.89M | 18.22M | 0 |
| Interest Expense | 352K | 1.42M | 153K | 149K | 0 | 349.76M | 0 |
| Other Income/Expense | 2.94M | 2.18M | 68.48M | 119.72M | -108.8M | -332.89M | 24.2M |
| Pretax Income | 1.42M▲ 0% | 11.4M▲ 705.4% | 82.31M▲ 622.2% | 120.76M▲ 46.7% | -75.56M▼ 162.6% | -275.98M▼ 265.2% | 90.68M▲ 132.9% |
| Pretax Margin % | 0.82% | 5.85% | 33.42% | 44.62% | -23.24% | -68.79% | 19.06% |
| Income Tax | 3.29M | 5.62M | 10.91M | -45K | 5.54M | 7.02M | 12.35M |
| Effective Tax Rate % | 232.58% | 49.28% | 13.25% | -0.04% | -7.33% | -2.54% | 13.62% |
| Net Income | -1.88M▲ 0% | 5.78M▲ 408.2% | 71.4M▲ 1135.0% | 120.81M▲ 69.2% | -81.1M▼ 167.1% | -283.01M▼ 249.0% | 78.33M▲ 127.7% |
| Net Margin % | -1.09% | 2.97% | 28.99% | 44.64% | -24.95% | -70.54% | 16.47% |
| Net Income Growth % | - | 408.16% | 1135.01% | 69.2% | -167.13% | -248.96% | 127.68% |
| Net Income (Continuing) | -1.88M | 5.78M | 71.4M | 120.81M | -81.1M | -283.01M | 78.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | 0.03▲ 409.0% | 0.44▲ 1323.9% | 0.59▲ 34.1% | -0.43▼ 172.9% | -1.35▼ 214.0% | 0.31▲ 123.0% |
| EPS Growth % | - | 409% | 1323.95% | 34.09% | -172.88% | -213.95% | 122.96% |
| EPS (Basic) | -0.01 | 0.03 | 0.50 | 0.64 | -0.43 | -1.35 | 0.32 |
| Diluted Shares Outstanding | 187.17M | 187.17M | 161.54M | 195.39M | 190.15M | 209.47M | 249.9M |
| Basic Shares Outstanding | 187.17M | 187.17M | 144M | 182.69M | 190.15M | 209.47M | 252.67M |
| Dividend Payout Ratio | - | 172.98% | 140.06% | - | - | - | - |
CLBT Balance Sheet
Cellebrite DI Ltd. (CLBT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 261.88M | 324.27M | 273.21M | 295.93M | 422.08M | 567.59M | 575.85M |
| Cash & Short-Term Investments | 200.25M | 237.64M | 181.56M | 183.62M | 302.92M | 447.22M | 437.05M |
| Cash Only | 76.55M | 128.71M | 145.97M | 87.64M | 189.52M | 191.66M | 124.46M |
| Short-Term Investments | 123.71M | 108.93M | 35.59M | 95.98M | 113.41M | 255.56M | 312.59M |
| Accounts Receivable | 44.24M | 66.32M | 67.5M | 78.76M | 77.27M | 82.36M | 104.97M |
| Days Sales Outstanding | 93.95 | 124.2 | 100.06 | 106.22 | 86.75 | 74.93 | 80.55 |
| Inventory | 3.96M | 4.75M | 6.51M | 10.18M | 9.94M | 8.94M | 7.6M |
| Days Inventory Outstanding | 40.35 | 45.81 | 55.84 | 73.19 | 68.16 | 52.13 | 36.92 |
| Other Current Assets | 8.86M | 11.24M | 7.88M | 14.77M | 23.06M | 18.18M | 6.59M |
| Total Non-Current Assets | 18.36M | 40.12M | 66.57M | 107.36M | 123.86M | 122.97M | 363M |
| Property, Plant & Equipment | 14.82M | 16.11M | 16.76M | 32.91M | 30.16M | 27.6M | 38.52M |
| Fixed Asset Turnover | 11.59x | 12.10x | 14.70x | 8.22x | 10.78x | 14.54x | 12.35x |
| Goodwill | 0 | 9.46M | 26.83M | 26.83M | 26.83M | 28.71M | 119.56M |
| Intangible Assets | 0 | 6.61M | 11.23M | 11.25M | 10.59M | 11.31M | 81.47M |
| Long-Term Investments | 0 | 0 | 0 | 22.13M | 28.86M | 36.6M | 97.96M |
| Other Non-Current Assets | 447K | 565K | 1.96M | 1.73M | 12.89M | 7.68M | 25.5M |
| Total Assets | 280.24M▲ 0% | 364.39M▲ 30.0% | 339.78M▼ 6.8% | 403.29M▲ 18.7% | 532.88M▲ 32.1% | 690.57M▲ 29.6% | 938.85M▲ 36.0% |
| Asset Turnover | 0.61x | 0.53x | 0.72x | 0.67x | 0.61x | 0.58x | 0.51x |
| Asset Growth % | - | 30.03% | -6.75% | 18.69% | 32.13% | 29.59% | 35.95% |
| Total Current Liabilities | 99.16M | 159.38M | 186.57M | 207.78M | 253.82M | 295.5M | 369.66M |
| Accounts Payable | 5.36M | 4.73M | 9.55M | 4.61M | 8.28M | 11.08M | 16.83M |
| Days Payables Outstanding | 54.61 | 45.55 | 81.87 | 33.17 | 56.79 | 64.59 | 81.74 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 69.79M | 106.1M | 123.68M | 153.34M | 196.59M | 217.64M | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 9.04M | 0 | 348.83M |
| Current Ratio | 2.64x | 2.03x | 1.46x | 1.42x | 1.66x | 1.92x | 1.56x |
| Quick Ratio | 2.60x | 2.00x | 1.43x | 1.38x | 1.62x | 1.89x | 1.54x |
| Cash Conversion Cycle | 79.69 | 124.46 | 74.03 | 146.24 | 98.12 | 62.46 | 35.73 |
| Total Non-Current Liabilities | 122.25M | 141.2M | 226.56M | 121.65M | 244.85M | 59.05M | 84.88M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 10.35M | 9.16M | 6.84M | 18.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 103.32M | 107.76M | 190.13M | 69.13M | 188.59M | 6.95M | 66.2M |
| Total Liabilities | 221.41M | 300.58M | 413.13M | 329.43M | 498.67M | 354.55M | 454.53M |
| Total Debt | 0 | 0 | 0 | 15.36M | 14.13M | 10.97M | 22.67M |
| Net Debt | -76.55M | -128.71M | -145.97M | -72.29M | -175.39M | -180.69M | -101.79M |
| Debt / Equity | - | - | - | 0.21x | 0.41x | 0.03x | 0.05x |
| Debt / EBITDA | - | - | - | 1.50x | 0.33x | 0.16x | 0.29x |
| Net Debt / EBITDA | -29.91x | -8.53x | -7.01x | -7.06x | -4.06x | -2.68x | -1.30x |
| Interest Coverage | -4.32x | 6.48x | 90.34x | 7.01x | - | 0.16x | - |
| Total Equity | 58.83M▲ 0% | 63.8M▲ 8.5% | -73.35M▼ 215.0% | 73.86M▲ 200.7% | 34.21M▼ 53.7% | 336.02M▲ 882.2% | 484.32M▲ 44.1% |
| Equity Growth % | - | 8.46% | -214.96% | 200.71% | -53.68% | 882.17% | 44.13% |
| Book Value per Share | 0.31 | 0.34 | -0.45 | 0.38 | 0.18 | 1.60 | 1.94 |
| Total Shareholders' Equity | 58.83M | 63.8M | -73.35M | 73.86M | 34.21M | 336.02M | 484.32M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 32.56M | 28.34M | 78.44M | 199.24M | 118.14M | -164.86M | -86.54M |
| Treasury Stock | 0 | -85K | -85K | -85K | -85K | -85K | -85K |
| Accumulated OCI | 804K | 1.32M | 1.37M | 331K | 1.05M | 2.09M | 2.22M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLBT Cash Flow Statement
Cellebrite DI Ltd. (CLBT) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 16.13M | 66.51M | 36.05M | 20.58M | 102.06M | 132.17M | 173.54M |
| Operating CF Margin % | 9.39% | 34.12% | 14.64% | 7.6% | 31.39% | 32.94% | 36.48% |
| Operating CF Growth % | - | 312.26% | -45.79% | -42.92% | 395.98% | 29.51% | 31.3% |
| Net Income | -1.88M | 5.78M | 71.4M | 120.81M | -81.1M | -283.01M | 78.33M |
| Depreciation & Amortization | 4.08M | 5.88M | 7.01M | 9.19M | 10.01M | 10.61M | 11.87M |
| Stock-Based Compensation | 12.76M | 7.27M | 6.48M | 13.71M | 19M | 30.57M | 0 |
| Deferred Taxes | -1.67M | -2.82M | -1.64M | -2.39M | 5.13M | -4.01M | 0 |
| Other Non-Cash Items | 131K | 689K | -67.87M | -117.92M | 110.5M | 335.96M | 91.46M |
| Working Capital Changes | 2.71M | 49.71M | 20.68M | -2.82M | 38.52M | 42.05M | -8.11M |
| Change in Receivables | -12.22M | -19.73M | -1.96M | -12.88M | 2.27M | -5.83M | -15.78M |
| Change in Inventory | 794K | -693K | -1.8M | -3.68M | 243K | 982K | 1.63M |
| Change in Payables | 974K | -1.43M | 4.24M | -5.47M | 3.69M | 2.75M | 0 |
| Cash from Investing | -46.72M | -6.45M | 45.23M | -91.23M | -22.54M | -149.47M | -268.25M |
| Capital Expenditures | -6.21M | -6.18M | -5.11M | -6.9M | -5.23M | -8.57M | -13.22M |
| CapEx % of Revenue | 3.61% | 3.17% | 2.08% | 2.55% | 1.61% | 2.14% | 2.78% |
| Acquisitions | 0 | -15.05M | -20M | 0 | 0 | -2.75M | -147.46M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -40.51M | 0 | -3M | -2.19M | -2.69M | -2.04M | -107.57M |
| Cash from Financing | 75.54M | -8.59M | -68.4M | 13.97M | 21.77M | 20.65M | 25.05M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | -85K | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | -25M | -10M | -100M | 0 | 0 | 0 | 0 |
| Share Repurchases | -808K | -85K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 141K | 1.49M | 31.6M | 13.97M | 21.77M | 20.65M | 25.05M |
| Net Change in Cash | 44.88M▲ 0% | 52.16M▲ 16.2% | 12.13M▼ 76.8% | -58.33M▼ 581.0% | 101.87M▲ 274.7% | 2.14M▼ 97.9% | -67.2M▼ 3237.3% |
| Free Cash Flow | 9.92M▲ 0% | 60.33M▲ 507.9% | 27.94M▼ 53.7% | 11.49M▼ 58.9% | 94.14M▲ 719.2% | 121.56M▲ 29.1% | 160.32M▲ 31.9% |
| FCF Margin % | 5.77% | 30.95% | 11.35% | 4.25% | 28.96% | 30.3% | 33.7% |
| FCF Growth % | - | 507.91% | -53.69% | -58.87% | 719.18% | 29.13% | 31.88% |
| FCF per Share | 0.05 | 0.32 | 0.17 | 0.06 | 0.50 | 0.58 | 0.64 |
| FCF Conversion (FCF/Net Income) | -8.60x | 11.50x | 0.50x | 0.17x | -1.26x | -0.47x | 2.22x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 3M | 2.91M | 8.16M | 9.05M | 10.05M | 7.71M | 0 |
CLBT Key Ratios
Cellebrite DI Ltd. (CLBT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -3.19% | 9.43% | - | 46642.86% | -150.08% | -152.88% | 19.1% |
| Return on Invested Capital (ROIC) | - | - | - | 49.68% | - | 603.07% | 18.54% |
| Gross Margin | 79.16% | 80.57% | 82.72% | 81.25% | 83.63% | 84.4% | 84.2% |
| Net Margin | -1.09% | 2.97% | 28.99% | 44.64% | -24.95% | -70.54% | 16.47% |
| Debt / Equity | - | - | - | 0.21x | 0.41x | 0.03x | 0.05x |
| Interest Coverage | -4.32x | 6.48x | 90.34x | 7.01x | - | 0.16x | - |
| FCF Conversion | -8.60x | 11.50x | 0.50x | 0.17x | -1.26x | -0.47x | 2.22x |
| Revenue Growth | - | 13.42% | 26.34% | 9.91% | 20.12% | 23.41% | 18.56% |
CLBT Frequently Asked Questions
Cellebrite DI Ltd. (CLBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cellebrite DI Ltd. (CLBT) reported $475.7M in revenue for fiscal year 2025. This represents a 177% increase from $171.9M in 2019.
Cellebrite DI Ltd. (CLBT) grew revenue by 18.6% over the past year. This is strong growth.
Yes, Cellebrite DI Ltd. (CLBT) is profitable, generating $78.3M in net income for fiscal year 2025 (16.5% net margin).
Dividend & Returns
Cellebrite DI Ltd. (CLBT) has a return on equity (ROE) of 19.1%. This is reasonable for most industries.
Cellebrite DI Ltd. (CLBT) generated $160.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CLBT
Cellebrite DI Ltd. (CLBT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates